GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.
Beurel, Eléonore
GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. [electronic resource] - Experimental cell research Nov 2004 - 354-64 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
0014-4827
10.1016/j.yexcr.2004.08.001 doi
Apoptosis--drug effects
Camptothecin--pharmacology
Etoposide--pharmacology
Gene Expression Regulation--physiology
Glycogen Synthase Kinase 3--antagonists & inhibitors
Glycogen Synthase Kinase 3 beta
Humans
Lithium--pharmacology
Promoter Regions, Genetic--physiology
Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Tumor Suppressor Protein p53--metabolism
fas Receptor--biosynthesis
GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. [electronic resource] - Experimental cell research Nov 2004 - 354-64 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
0014-4827
10.1016/j.yexcr.2004.08.001 doi
Apoptosis--drug effects
Camptothecin--pharmacology
Etoposide--pharmacology
Gene Expression Regulation--physiology
Glycogen Synthase Kinase 3--antagonists & inhibitors
Glycogen Synthase Kinase 3 beta
Humans
Lithium--pharmacology
Promoter Regions, Genetic--physiology
Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Tumor Suppressor Protein p53--metabolism
fas Receptor--biosynthesis